Pfizer Shares Update on Oral GLP-1 Candidate Danuglipron
Pfizer Inc. announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for…
Read More...
Read More...